Enliven Therapeutics, Inc.
NMS: ELVNLive Quote
About Enliven Therapeutics, Inc.
Healthcare
Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
📊 Fundamental Analysis
Enliven Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -27.0%, which indicates that capital utilization is currently under pressure.
At a current price of $45.32, ELVN currently trades near the top of its 52-week range (97%) (Range: $14.79 - $46.31).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$2.20B
Trailing P/E
--
Forward P/E
-17.84
Beta (5Y)
0.49
52W High
$46.31
52W Low
$14.79
Avg Volume
1.17M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App